These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 36843949)

  • 21. Identification of a prognostic cuproptosis-related signature in hepatocellular carcinoma.
    Chen Y; Tang L; Huang W; Abisola FH; Zhang Y; Zhang G; Yao L
    Biol Direct; 2023 Feb; 18(1):4. PubMed ID: 36750831
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cuproptosis-related molecular patterns and gene (ATP7A) in hepatocellular carcinoma and their relationships with tumor immune microenvironment and clinical features.
    Li S; Weng J; Xiao C; Lu J; Cao W; Song F; He Z; Zhang P; Zhu Z; Xu J
    Cancer Rep (Hoboken); 2023 Dec; 6(12):e1904. PubMed ID: 37885090
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characterization of a cuproptosis-related signature to evaluate immune features and predict prognosis in colorectal cancer.
    Li L; Sun F; Kong F; Feng Y; Song Y; Du Y; Liu F; Kong X
    Front Oncol; 2023; 13():1083956. PubMed ID: 37384293
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cuproptosis regulator-mediated patterns associated with immune infiltration features and construction of cuproptosis-related signatures to guide immunotherapy.
    Wang G; Xiao R; Zhao S; Sun L; Guo J; Li W; Zhang Y; Bian X; Qiu W; Wang S
    Front Immunol; 2022; 13():945516. PubMed ID: 36248857
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Crosstalk of cuproptosis-related prognostic signature and competing endogenous RNAs regulation in hepatocellular carcinoma.
    Zhu J; Wang J; Liu H; Lei T; Yang J; Lan S; Jian H; Fang H; Zhang Y; Ren K; Zhong F
    Aging (Albany NY); 2023 Dec; 15(23):13901-13919. PubMed ID: 38078880
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of a novel cuproptosis-related gene signature and integrative analyses in patients with lower-grade gliomas.
    Bao JH; Lu WC; Duan H; Ye YQ; Li JB; Liao WT; Li YC; Sun YP
    Front Immunol; 2022; 13():933973. PubMed ID: 36045691
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Copper and cuproptosis-related genes in hepatocellular carcinoma: therapeutic biomarkers targeting tumor immune microenvironment and immune checkpoints.
    Wang X; Chen D; Shi Y; Luo J; Zhang Y; Yuan X; Zhang C; Shu H; Yu W; Tian J
    Front Immunol; 2023; 14():1123231. PubMed ID: 37153542
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Single-cell and genetic multi-omics analysis combined with experiments confirmed the signature and potential targets of cuproptosis in hepatocellular carcinoma.
    Cao F; Qi Y; Wu W; Li X; Yang C
    Front Cell Dev Biol; 2023; 11():1240390. PubMed ID: 37745297
    [No Abstract]   [Full Text] [Related]  

  • 29. Comprehensive analysis of cuproptosis-related lncRNAs in immune infiltration and prognosis in hepatocellular carcinoma.
    Liu C; Wu S; Lai L; Liu J; Guo Z; Ye Z; Chen X
    BMC Bioinformatics; 2023 Jan; 24(1):4. PubMed ID: 36597032
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification and validation of a novel cuproptosis-related signature as a prognostic model for lung adenocarcinoma.
    Chen Y; Tang L; Huang W; Zhang Y; Abisola FH; Li L
    Front Endocrinol (Lausanne); 2022; 13():963220. PubMed ID: 36353226
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic and immune correlation evaluation of a novel cuproptosis-related genes signature in hepatocellular carcinoma.
    Zhou Z; Zhou Y; Liu D; Yang Q; Tang M; Liu W
    Front Pharmacol; 2022; 13():1074123. PubMed ID: 36588699
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characterization of cuproptosis in gastric cancer and relationship with clinical and drug reactions.
    Chen G; Luo D; Qi X; Li D; Zheng J; Luo Y; Zhang C; Ren Q; Lu Y; Chan YT; Chen B; Wu J; Wang N; Feng Y
    Front Cell Dev Biol; 2023; 11():1172895. PubMed ID: 37351275
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cuproptosis-related long non-coding RNAs model that effectively predicts prognosis in hepatocellular carcinoma.
    Huang EM; Ma N; Ma T; Zhou JY; Yang WS; Liu CX; Hou ZH; Chen S; Zong Z; Zeng B; Li YR; Zhou TC
    World J Gastrointest Oncol; 2022 Oct; 14(10):1981-2003. PubMed ID: 36310708
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A novel cuproptosis-related prognostic gene signature in adrenocortical carcinoma.
    Gao W; He X; Huangfu Q; Xie Y; Chen K; Sun C; Wei J; Wang B
    J Clin Lab Anal; 2023 Nov; 37(21-22):e24981. PubMed ID: 37997497
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A cuproptosis random forest cox score model-based evaluation of prognosis, mutation characterization, immune infiltration, and drug sensitivity in hepatocellular carcinoma.
    Liu R; Liu Y; Zhang F; Wei J; Wu L
    Front Immunol; 2023; 14():1146411. PubMed ID: 37063920
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of the cuproptosis-related molecular subtypes and an immunotherapy prognostic model in hepatocellular carcinoma.
    Zhang L; Xu J; Chu X; Zhang H; Yao X; Zhang J; Guo Y
    BMC Bioinformatics; 2022 Nov; 23(1):485. PubMed ID: 36384423
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic and metabolic characteristics of a novel cuproptosis-related signature in patients with hepatocellular carcinoma.
    Qu X; Meng LC; Lu X; Chen X; Li Y; Zhou R; Zhu YJ; Luo YC; Huang JT; Shi XL; Zhang HB
    Heliyon; 2024 Jan; 10(1):e23686. PubMed ID: 38259960
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comprehensive Analysis of Cuproptosis-Related Genes in Prognosis and Immune Infiltration of Hepatocellular Carcinoma Based on Bulk and Single-Cell RNA Sequencing Data.
    Yang C; Guo Y; Wu Z; Huang J; Xiang B
    Cancers (Basel); 2022 Nov; 14(22):. PubMed ID: 36428805
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cuproptosis-related immune checkpoint gene signature: Prediction of prognosis and immune response for hepatocellular carcinoma.
    Cong T; Luo Y; Liu Y; Yang C; Yang H; Li Y; Li J; Li X
    Front Genet; 2022; 13():1000997. PubMed ID: 36276933
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A novel cuproptosis-related prognostic signature and potential value in HCC immunotherapy.
    Wang XX; Wu LH; Ji H; Liu QQ; Deng SZ; Dou QY; Ai L; Pan W; Zhang HM
    Front Mol Biosci; 2022; 9():1001788. PubMed ID: 36250008
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.